This question tests the management of chronic pediatric conditions, specifically focusing on long-term care strategies and coordination with interdisciplinary teams. Chronic conditions like type 1 diabetes in teens can involve psychosocial issues like disordered eating, requiring mental health support. In this vignette, intentional insulin omission for weight control signals an eating disorder risk needing specialized intervention. Choice A is correct because consulting a mental health specialist addresses diabulimia per ADA recommendations. Choice B is incorrect because orthopedic evaluation isn't indicated without neuropathy evidence. To help students: Emphasize screening for psychosocial complications in diabetes. Practice identifying red flags for referral in adolescent care.

When evaluating long-term complications in patients with Fontan circulation, focus on how the altered hemodynamics affect organ systems over time. The Fontan procedure creates a single-ventricle circulation where systemic venous return flows passively to the pulmonary arteries without a pumping chamber, resulting in chronically elevated central venous pressures.

The correct answer is D because chronic liver disease and fibrosis represent the most significant long-term risk in Fontan patients. The persistently elevated central venous pressure (typically 12-15 mmHg compared to normal 2-8 mmHg) causes chronic hepatic congestion. This leads to progressive liver fibrosis, cirrhosis, and eventually hepatocellular carcinoma in some patients. This complication, known as Fontan-associated liver disease (FALD), affects nearly all long-term Fontan survivors and is now a leading cause of morbidity and mortality in this population.

Option A is incorrect because progressive aortic stenosis isn't a characteristic complication of Fontan circulation. Option B is wrong because Fontan patients typically develop polycythemia (increased red blood cells) due to chronic mild hypoxemia, not iron-deficiency anemia. Option C is incorrect because while endocarditis risk exists in congenital heart disease, it's not the primary long-term concern specific to Fontan circulation compared to liver disease.

Remember that Fontan physiology creates a high-pressure, low-flow venous system. When you see Fontan follow-up questions, immediately think about complications related to elevated venous pressures: liver disease, protein-losing enteropathy, arrhythmias, and thromboembolism. Liver disease is the most universal and progressive of these complications.

This adolescent with long-standing type 1 diabetes has suboptimal glycemic control (HbA1c > 7.5%) and demonstrates difficulty with the complexities of a multiple daily injection regimen, particularly with postprandial glucose excursions. Referral for evaluation for an insulin pump and continuous glucose monitoring (CGM) is the most appropriate next step. This technology provides more physiologic insulin delivery, allows for real-time glucose data to guide therapy, and can improve glycemic control and quality of life, especially in adolescents struggling with regimen adherence and complexity.

Hydroxyurea is a disease-modifying therapy that increases the production of fetal hemoglobin (HbF), which interferes with the polymerization of sickle hemoglobin. It is indicated for children with sickle cell anemia (HbSS) who experience frequent vaso-occlusive crises (typically defined as ≥3 moderate-to-severe crises in a 12-month period). This patient meets the criteria, and initiating hydroxyurea is the most effective intervention to reduce the frequency of both pain crises and acute chest syndrome.

This patient's gradual decline in lung function and nutritional status, despite standard therapies, suggests disease progression. For a patient who is homozygous for the F508del mutation, initiation of a highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulator (e.g., elexacaftor/tezacaftor/ivacaftor) is the most appropriate step. These agents target the underlying protein defect, leading to significant improvements in lung function, nutritional status, and quality of life.

The patient has focal spasticity in his lower extremities that is interfering with care and causing pain. Referral to a specialist (e.g., neurologist, physiatrist) for consideration of botulinum toxin injections is the most appropriate next step. Botulinum toxin is a first-line treatment for focal spasticity in cerebral palsy, as it can reduce muscle tone in targeted muscles, improve range of motion, and facilitate easier care and therapy. While oral baclofen can be used, it is more for generalized spasticity and has systemic side effects. Hip surveillance is important but does not address the acute problem of spasticity. Discontinuing therapy would be detrimental.

Children with Down syndrome are at a significantly increased risk for autoimmune hypothyroidism. The AAP health supervision guidelines recommend screening with a TSH level at birth, 6 months, 12 months, and then annually throughout life. Therefore, obtaining a TSH level is the indicated screening test at this 4-year-old well-child visit. An echocardiogram should have been done in infancy. Cervical spine radiographs are only recommended for symptomatic children. A sleep study is recommended between ages 3 and 4, so it might be appropriate, but annual thyroid screening is a consistent requirement.

This patient has hyperphosphatemia and secondary hyperparathyroidism, characteristic of CKD-mineral and bone disorder. The cornerstone of initial management is controlling the serum phosphorus level. This is achieved through dietary phosphorus restriction and the use of phosphate binders taken with meals to prevent absorption of dietary phosphate. Starting a phosphate binder is the first and most critical step. Administering active vitamin D before controlling phosphorus can worsen hyperphosphatemia and lead to vascular calcification.

When you encounter questions about congenital heart disease in adults, focus on the long-term sequelae and ongoing management needs rather than immediate acute concerns.

Tetralogy of Fallot repair, while life-saving, creates predictable long-term complications. The surgical correction typically involves patch repair of the ventricular septal defect and relief of pulmonary stenosis, but this often results in pulmonary regurgitation. Over decades, chronic volume overload from pulmonary regurgitation leads to progressive right ventricular dilation, dysfunction, and eventually heart failure. Additionally, surgical scarring and chronic hemodynamic changes create substrate for arrhythmias, particularly ventricular tachycardia and sudden cardiac death. This patient already shows early signs with moderate pulmonary regurgitation and mild RV dilation, making choice A correct.

Choice B is incorrect because current guidelines don't recommend routine endocarditis prophylaxis for repaired Tetralogy of Fallot without residual defects. Choice C represents a dangerous misconception—congenital heart disease patients require lifelong cardiac surveillance even after "successful" repair, as complications typically emerge decades later. Choice D is overly restrictive; while competitive athletics may require evaluation, recreational sports are generally safe with normal RV function and no arrhythmias.

Study tip: For USMLE Step 3, remember that "repaired" congenital heart disease doesn't mean "cured." These patients face predictable late complications based on their specific anatomy and repair type. Focus on the long-term hemodynamic consequences rather than immediate post-operative concerns.

The most compelling reason is the natural history of the specific epilepsy syndrome. Juvenile myoclonic epilepsy (JME) is a genetic generalized epilepsy that is well-controlled with medication but has a very high relapse rate (75-95%) when medication is withdrawn, even after many years of seizure freedom. It is typically considered a lifelong condition requiring lifelong treatment. While the stress of college is a valid concern for any epilepsy patient (Distractor D), the fundamental biology of JME is the primary contraindication to stopping medication.